AstraZeneca Rating Reiterated by Shore Capital Stockbrokers (AZN)

Share on StockTwits

AstraZeneca (LON: AZN)‘s stock had its “buy” rating reaffirmed by investment analysts at Shore Capital Stockbrokers in a note issued to investors on Monday, Analyst Ratings.Net reports.

Shares of AstraZeneca (LON: AZN) opened at 3332.2881 on Monday. AstraZeneca has a one year low of GBX 2633.50 and a one year high of GBX 3544.50. The stock’s 50-day moving average is currently GBX 2919.40. The company’s market cap is £41.654 billion.

AZN has been the subject of a number of other recent research reports. Analysts at Galvan Research reiterated a “buy” rating on shares of AstraZeneca in a research note to investors on Monday. They now have a GBX 3,500 ($53.33) price target on the stock. Separately, analysts at UBS AG reiterated a “buy” rating on shares of AstraZeneca in a research note to investors on Friday. They now have a GBX 3,600 ($54.85) price target on the stock. Finally, analysts at AlphaValue reiterated a “reduce” rating on shares of AstraZeneca in a research note to investors on Wednesday, June 5th. They now have a GBX 3,371 ($51.36) price target on the stock.

Ten research analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of GBX 4,154.91 ($63.31).

AstraZeneca PLC (LON: AZN) is a global biopharmaceutical company.

Latest News

Another Hack on a Payment Card System
Another Hack on a Payment Card System
Private Social Network Ello Generating Buzz
Private Social Network Ello Generating Buzz
Data Breaches at Record Highs for 2014
Data Breaches at Record Highs for 2014
Activist Investor Insists Yahoo Buy AOL
Activist Investor Insists Yahoo Buy AOL
Nike Profit Driven by Higher Margins and Demand Across Europe
Nike Profit Driven by Higher Margins and Demand Across Europe
New Home Sales Soar in August
New Home Sales Soar in August


Leave a Reply

 
 
© 2006-2014 Ticker Report. Google+.